Rampart Health Bursts Out of Stealth Mode to Report 77% Disease Control in Metastatic Cancer from First-in-Human Phase 2 Trial ("Abscopal 5001") of Multiplex Intra-tumoral Immunotherapy (MITI)
06 Nov 2023
Clinical ResultImmunotherapyPhase 2ASCOAACR
MITI was safe and well tolerated as a rapid outpatient treatment.
Disease control (significant shrinkage or stabilization of cancer) seen in 77%.
Untreated metastases regressed in 31% (Abscopal Effect).
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Rampart Health, a company dedicated to harnessing the abscopal effect for cure in patients with metastatic cancer, announced positive preliminary results of the first-ever prospective trial of a novel treatment delivered directly into cancer at the Society of Immunotherapy in Cancer Annual Meeting.
Thirteen patients received at least one intra-tumoral treatment of
Multiplex
Intra-
Tumoral
Immunotherapy (
MITI) consisting of cryo-ablation followed by intra-tumoral injection of PD-1 and CTLA-4 inhibitorsCTLA-4 inhibitors and cyclophosphamide; GM-CSF was administered subcutaneously. There were no grade 4 or 5 side effects. Partial response was observed in 5 patients (38.5%) and stable disease in 5 (38.5%), for a disease control rate of 77%. The Abscopal Effect (cancer resolution at untreated metastatic sites) was seen in 4 (31%), including complete responses of lung metastases in one patient with sarcoma and liver metastases in one with bladder cancer.
CEO David G. Bostwick MD, MBA, said "Results of the Abscopal 5001 trial prospectively demonstrate the potential of our novel intra-tumoral treatment (MITI) to handle one of the world's most devastating and difficult diseases: metastatic cancer. Our vision is to empower the patient's immune system to destroy cancer by exploiting four processes: (1) Releasing by ablation the full complement of cancer-specific protein antigens; (2) Unmasking by immunotherapy all cancer-specific antigens to ensure optimal recognition by the immune system; (3); Unleashing the full force of the cancer-killing T-cells and other immune cells by activation and mobilization; and (4) Blocking mechanisms that would dampen the anti-tumor effect. We were gratified by the high rates of Disease Control and Abscopal Effect, as well as the favorable Adverse Event profile compared with systemic immunotherapy. Remarkably, this therapy appeared to be applicable to many types of solid cancer."
About Rampart Health
Rampart Health is a clinical service-based, development-stage company that has pioneered the personalized
Multiplex
Intra-
Tumoral
Immunotherapy (
MITI) treatment to synergistically empower the immune system to destroy cancer (www.ramparthealth.com).
INVESTOR and MEDIA CONTACT
David G. Bostwick MD, MBA
[email protected]
SOURCE Rampart Health
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.